BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [The role of hyperhomocysteinemia in systemic lupus erythematosus and antiphospholipid syndrome].

AIM: To assess the role of hyperhomocysteinemia (HHC) in development of vascular complications in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS).

The patients had the disease for 14 +/- 11 years.

HHC (HC > 15 mcg/l) was diagnosed in 82 of 125 (66%) patients: in 59% patients of group 1, 67%--of group 2 and 76%--of group 3.

There was a relationship between HHC and digital necrosis (DN): 80% of DN patients had HHC while HHC was diagnosed in 57% patients free of DN (chi-square = 4.76, p = 0.03).

Elevated levels of HC in blood was registered in 43 of 55 (78%) APS patients with thromboses vs. 9 of 19 (47%) patients with APS free of thromboses (p = 0.03).

HHC occurred significantly more frequently in patients with arterial thromboses (in all 14 patients) than in patients with venous thromboses (in 16 of 23--69.6%, p = 0.03) and in the absence of thromboses (in 9 of 19, 47.4%, p = 0.04).

CONCLUSION: More than 50% patients with SLE and APS, irrespective of APS variants, had an elevated HC level in the blood.

[MeSH-major] Antiphospholipid Syndrome / epidemiology. Hyperhomocysteinemia / epidemiology. Hyperhomocysteinemia / physiopathology. Lupus Erythematosus, Systemic / epidemiology

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Lupus.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16881359.001).

[ISSN] 0040-3660

[Journal-full-title] Terapevticheskiĭ arkhiv

[ISO-abbreviation] Ter. Arkh.

[Language] rus

[Publication-type] English Abstract; Journal Article

[Publication-country] Russia (Federation)

[Chemical-registry-number] 0 / Antibodies, Anticardiolipin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-affinity T cell receptor differentiates cognate peptide-MHC and altered peptide ligands with distinct kinetics and thermodynamics.

Interactions between the T cell receptor and cognate peptide-MHC are crucial initiating events in the adaptive immune response.

In this work, we used M15, a high-affinity TCR engineered from the 3.L2 TCR system, to study the binding properties, thermodynamics, and specificity of two altered peptide ligands (APLs).

Our affinity measurements of the high-affinity TCR support the view that the wild type TCR binds these APLs in the millimolar affinity range, and hence very low affinities can still elicit biological functions.

As the identical TCR was analyzed with several structurally similar ligands, the distinct thermodynamic binding profiles provide a mechanistic perspective on how exquisite antigen specificity is achieved by the T cell receptor.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2010 Elsevier Ltd. All rights reserved.

[Cites] Immunity. 2000 Oct;13(4):475-84 [11070166.001]

[Cites] Biomol Eng. 2007 Oct;24(4):361-73 [17409021.001]

[Cites] J Mol Biol. 2001 Apr 13;307(5):1305-15 [11292343.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6818-23 [11391002.001]

[Cites] Biochemistry. 2001 Sep 11;40(36):10764-73 [11535051.001]

[Cites] Nat Immunol. 2002 Mar;3(3):244-50 [11836529.001]

[Cites] Nature. 2002 Aug 1;418(6897):552-6 [12152083.001]

[Cites] Nat Immunol. 2003 Jan;4(1):55-62 [12469116.001]

[Cites] J Mol Biol. 2003 Jan 31;325(5):991-1018 [12527304.001]

[Cites] Annu Rev Immunol. 2003;21:659-84 [12615890.001]

[Cites] Biochemistry. 2003 Apr 29;42(16):4709-16 [12705834.001]

[Cites] J Biol Chem. 2003 Nov 14;278(46):46146-54 [12933789.001]

[Cites] J Immunol. 2003 Nov 15;171(10):5587-95 [14607967.001]

[Cites] Mol Cell. 2003 Dec;12(6):1367-78 [14690592.001]

[Cites] Gene Ther. 2004 Aug;11(15):1234-9 [15215883.001]

[Cites] Science. 1991 May 31;252(5010):1308-10 [1833816.001]

[Cites] Adv Protein Chem. 1992;43:313-61 [1442323.001]

[Cites] Proteins. 1993 Feb;15(2):113-20 [8441749.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10330-4 [8234294.001]

[Cites] Cell. 1994 Dec 2;79(5):913-22 [8001128.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12862-6 [7809136.001]

[Cites] Immunity. 1994 Apr;1(1):15-22 [7889394.001]

[Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):5042-6 [7761445.001]

[Cites] Annu Rev Immunol. 1995;13:93-126 [7612239.001]

[Cites] Nature. 1996 Apr 11;380(6574):495-8 [8606766.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1401-5 [8643643.001]

[Cites] Immunity. 1996 Jul;5(1):53-61 [8758894.001]

[Cites] Immunity. 1996 Sep;5(3):217-28 [8808677.001]

[Cites] J Exp Med. 1996 Oct 1;184(4):1525-30 [8879224.001]

[Cites] J Exp Med. 1997 Oct 20;186(8):1223-32 [9334361.001]

[Cites] J Exp Med. 1997 Oct 20;186(8):1269-75 [9334366.001]

[Cites] Annu Rev Immunol. 1998;16:523-44 [9597140.001]

[Cites] Immunity. 1998 Dec;9(6):817-26 [9881972.001]

[Cites] Immunity. 1999 Mar;10(3):357-65 [10204491.001]

[Cites] J Exp Med. 1999 May 17;189(10):1531-44 [10330432.001]

[Cites] Immunity. 1999 Aug;11(2):173-81 [10485652.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11446-51 [10500196.001]

[Cites] J Exp Med. 2004 Dec 6;200(11):1455-66 [15583017.001]

[Cites] J Mol Biol. 2005 Feb 18;346(2):533-50 [15670602.001]

[Cites] Mol Cell. 2005 Feb 18;17(4):513-23 [15721255.001]

[Cites] Nature. 2005 Mar 10;434(7030):238-43 [15724150.001]

[Cites] Nat Immunol. 2005 Aug;6(8):785-92 [15980863.001]

[Cites] EMBO J. 2005 Sep 7;24(17):2968-79 [16079912.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19033-8 [16365315.001]

[Cites] Mol Immunol. 2006 Mar;43(9):1349-57 [16216327.001]

[Cites] Annu Rev Immunol. 2006;24:419-66 [16551255.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4416-21 [16537380.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6641-6 [16617112.001]

[Cites] Nat Immunol. 2006 Nov;7(11):1191-9 [17041605.001]

[Cites] J Immunol. 2006 Nov 15;177(10):6911-9 [17082606.001]

[Cites] J Exp Med. 2007 Jan 22;204(1):49-55 [17210731.001]

[Cites] Nat Immunol. 2007 Apr;8(4):398-408 [17334368.001]

[Cites] EMBO J. 2007 Apr 4;26(7):1972-83 [17363906.001]

[Cites] Cell. 2007 Apr 6;129(1):135-46 [17418792.001]

[Cites] J Immunol. 2007 May 1;178(9):5488-95 [17442930.001]

[Cites] Nat Med. 2007 Jun;13(6):725-9 [17515896.001]

[Cites] J Immunol. 2001 Mar 1;166(5):3345-54 [11207290.001]

(PMID = 20334923.001).

[ISSN] 1872-9142

[Journal-full-title] Molecular immunology

[ISO-abbreviation] Mol. Immunol.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / AI061173-05; United States / NIAID NIH HHS / AI / R37 AI024157-24; United States / NIAID NIH HHS / AI / AI024157-24; United States / NIAID NIH HHS / AI / P01 AI071195-040002; United States / NIAID NIH HHS / AI / R37 AI024157; United States / NIAID NIH HHS / AI / R01 AI061173-05; United States / NIAID NIH HHS / AI / P01 AI071195; United States / NIAID NIH HHS / AI / R01 AI061173; United States / NIAID NIH HHS / AI / AI071195-040002

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Histocompatibility Antigens Class II; 0 / Ligands; 0 / Peptides; 0 / Receptors, Antigen, T-Cell

[Other-IDs] NLM/ NIHMS191933; NLM/ PMC2860700

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients.

OBJECTIVES: This study was to evaluate the relationship between clozapine and aPL in schizophrenia patients.

A fasting blood sample was taken for serum aPL and serum clozapine level.

Serum aPL were measured by ELISA technique and HPLC method was used for the determination of serum clozapine level.

RESULTS: The unmedicated schizophrenia patients showed higher IgG aCL level [mean+/-SD: 1.51+/-0.81 and 1.25+/-0.13 U, respectively (t=2.77, df=111, p<0.01)] and IgM aCL level [mean+/-SD: 1.53+/-0.54. and 1.33+/-0.15 U, respectively (t=-2.98, df=111, p<0.01)] compared with the healthy controls.

The comparison of the clozapine-treated schizophrenia patients and the healthy controls showed significant difference in IgG aCL level [mean+/-SD: 1.74+/-0.90 and 1.25+/-0.13 U, respectively (t=-4.77, df=124, p<0.01)] and IgM aCL level [mean+/-SD: 1.62+/-0.83 and 1.33+/-0.15 U, respectively (t=-4.35, df=124, p<0.01)].

In clozapine-treated schizophrenia patients, the results of Pearson correlation coefficients showed that there was a significant positive relationship between serum IgM aCL and serum clozapine level (r=0.461, p<0.01), and serum IgG aCL were significantly correlated with serum IgM aCL (r=0.279, p<0.05).

Stepwise multiple regression analysis was performed with various characteristics, such as duration of medication, daily dose and serum clozapine level as candidate factors for serum aCL (IgG and IgM isotypes) in clozapine-treated schizophrenia patients.

Only serum clozapine level was able to enter into the regression model of IgM aCL (Model R(2)=0.212, p<0.05).

CONCLUSIONS: A higher serum clozapine level is associated with an increased aPL in schizophrenia patients.

[MeSH-major] Antibodies, Antiphospholipid / blood. Antipsychotic Agents / blood. Clozapine / blood. Schizophrenia / blood

Genetic Alliance. consumer health - Schizophrenia.

MedlinePlus Health Information. consumer health - Schizophrenia.

Hazardous Substances Data Bank. CLOZAPINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18976782.001).

[ISSN] 0022-3956

[Journal-full-title] Journal of psychiatric research

[ISO-abbreviation] J Psychiatr Res

[Language] eng

[Publication-type] Journal Article; Randomized Controlled Trial

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antipsychotic Agents; 0 / Immunoglobulin G; 0 / Immunoglobulin M; J60AR2IKIC / Clozapine

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Circulating oxLDL/beta2GPI complexes and autoantibodies to these complexes have been demonstrated in patients with systemic lupus erythematosus and antiphospholipid syndrome.

The in vitro macrophage uptake of oxLDL/beta2GPI complexes increased significantly in the presence of antiphospholipid antibodies (anti-beta2GPI), suggesting that macrophage Fcgamma receptors are involved in the lipid intracellular influx that leads to foam cell formation.

These findings provide an immunologic explanation for the accelerated development of atherosclerosis seen in systemic lupus erythematosus and antiphospholipid syndrome.

[MeSH-major] Antiphospholipid Syndrome / complications. Atherosclerosis / complications. Lupus Erythematosus, Systemic / complications

Genetic Alliance. consumer health - Autoimmune Diseases.

MedlinePlus Health Information. consumer health - Atherosclerosis.

MedlinePlus Health Information. consumer health - Lupus.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr Opin Lipidol. 1997 Oct;8(5):268-74 [9335950.001]

[Cites] Rheum Dis Clin North Am. 2006 Aug;32(3):537-51 [16880083.001]

[Cites] Clin Chem. 1992 Oct;38(10):2066-72 [1394991.001]

[Cites] Arthritis Rheum. 2005 Jul;52(7):2069-79 [15986354.001]

[Cites] Clin Immunol. 2002 Oct;105(1):81-92 [12483997.001]

[Cites] Lupus. 2008 Oct;17(10):878-87 [18827052.001]

[Cites] Lupus. 1998;7 Suppl 2:S132-4 [9814690.001]

[Cites] Prog Lipid Res. 2006 Nov;45(6):466-86 [16790279.001]

[Cites] Free Radic Biol Med. 2000 Jun 15;28(12):1717-25 [10946213.001]

[Cites] Clin Exp Immunol. 1997 Mar;107(3):569-73 [9067534.001]

[Cites] J Lipid Res. 2007 Apr;48(4):768-81 [17261875.001]

[Cites] J Exp Med. 1994 Feb 1;179(2):457-62 [7507506.001]

[Cites] Lupus. 1997;6(5):467-73 [9229367.001]

[Cites] Circulation. 1999 May 4;99(17):2227-30 [10226085.001]

[Cites] Stroke. 2001 Aug;32(8):1701-6 [11486093.001]

[Cites] Ann Rheum Dis. 2005 Feb;64(2):315-7 [15155372.001]

[Cites] Arch Intern Med. 2001 Nov 12;161(20):2433-9 [11700155.001]

[Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5134-8 [1695010.001]

[Cites] Nephron Clin Pract. 2004;98(1):c15-24 [15361700.001]

[Cites] J Lipid Res. 2002 Sep;43(9):1486-95 [12235181.001]

[Cites] Ann N Y Acad Sci. 2007 Jun;1108:475-80 [17894012.001]

[Cites] J Lipid Res. 2003 Apr;44(4):716-26 [12562869.001]

[Cites] Rheumatology (Oxford). 2008 Dec;47(12):1832-7 [18930964.001]

[Cites] J Lipid Res. 1987 Dec;28(12):1466-77 [3323390.001]

[Cites] Thromb Haemost. 1999 May;81(5):748-57 [10365749.001]

[Cites] Lupus. 1998;7(1):3-6 [9493141.001]

[Cites] Lancet. 1992 Apr 11;339(8798):883-7 [1348295.001]

[Cites] Nature. 1985 Aug 22-28;316(6030):680-1 [4033768.001]

[Cites] J Mol Biol. 2000 Dec 15;304(5):927-39 [11124037.001]

[Cites] Lupus. 2000;9(3):166-9 [10805482.001]

[Cites] J Lipid Res. 2001 May;42(5):697-709 [11352976.001]

[Cites] J Biol Chem. 2000 Dec 29;275(52):40663-6 [11060282.001]

[Cites] Atherosclerosis. 1993 Nov;103(2):213-9 [7507327.001]

[Cites] Arthritis Rheum. 2001 Oct;44(10):2331-7 [11665973.001]

[Cites] Lupus. 2007;16(12):929-38 [18042586.001]

[Cites] Autoimmun Rev. 2008 Jan;7(3):214-22 [18190881.001]

[Cites] J Biol Chem. 1997 Aug 22;272(34):20963-6 [9261091.001]

[Cites] Ann N Y Acad Sci. 2007 Jun;1108:594-602 [17894024.001]

[Cites] Cell. 1984 Nov;39(1):27-38 [6091915.001]

[Cites] Clin Dev Immunol. 2003 Jun-Dec;10(2-4):203-11 [14768953.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9580-4 [7568176.001]

[Cites] J Autoimmun. 2007 Sep-Nov;29(2-3):164-73 [17826950.001]

[Cites] Lupus. 2005;14(9):736-41 [16218478.001]

[Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]

[Cites] J Clin Invest. 1989 Oct;84(4):1086-95 [2794046.001]

[Cites] Blood. 2005 Feb 15;105(4):1552-7 [15486070.001]

[Cites] Ann N Y Acad Sci. 2005 Jun;1051:313-22 [16126973.001]

[Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120-4 [2349221.001]

[Cites] Am J Clin Pathol. 2004 Jan;121(1):142-9 [14750252.001]

[Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9238-42 [3194423.001]

[Cites] Blood. 2007 Dec 15;110(13):4312-8 [17726161.001]

[Cites] Br J Rheumatol. 1997 Dec;36(12):1247-57 [9448584.001]

[Cites] J Rheumatol. 1986 Jun;13(3):486-9 [3735270.001]

[Cites] Am J Clin Pathol. 2004 Mar;121(3):426-36 [15023048.001]

[Cites] Clin Rev Allergy Immunol. 2009 Aug;37(1):29-35 [18987784.001]

[Cites] Nature. 1997 Mar 6;386(6620):73-7 [9052782.001]

[Cites] Arthritis Rheum. 2005 Jan;52(1):192-200 [15641060.001]

[Cites] Arthritis Rheum. 2002 Apr;46(4):1019-27 [11953980.001]

[Cites] Ann N Y Acad Sci. 2007 Jun;1108:489-96 [17894014.001]

[Cites] Circulation. 2000 Oct 10;102(15):1822-7 [11023938.001]

[Cites] Eur Heart J. 1990 Aug;11 Suppl E:83-7 [2121485.001]

[Cites] Nature. 1998 Jul 9;394(6689):200-3 [9671306.001]

[Cites] Ann Intern Med. 1992 Dec 15;117(12):997-1002 [1443986.001]

(PMID = 19171113.001).

[ISSN] 1534-6307

[Journal-full-title] Current rheumatology reports

[ISO-abbreviation] Curr Rheumatol Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Autoantibodies; 0 / Lipoproteins, LDL; 0 / beta 2-Glycoprotein I; 0 / oxidized low density lipoprotein

[Number-of-references] 64

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Treatment of acute promyelocytic leukemia].

[MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17474452.001).

[ISSN] 0047-1852

[Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine

[ISO-abbreviation] Nippon Rinsho

[Language] jpn

[Publication-type] Journal Article; Review

[Publication-country] Japan

[Chemical-registry-number] 5688UTC01R / Tretinoin

[Number-of-references] 15

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We describe a 38-year-old woman with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) who developed two symmetric paramalleolar ulcers with similar diameters, depths and borders, that were successfully treated with photodynamic therapy with 5-aminolevulinic acid (ALA-PDT).

[MeSH-minor] Adult. Aminolevulinic Acid / therapeutic use. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / drug therapy. Antiphospholipid Syndrome / pathology. Female. Humans. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Lupus Erythematosus, Systemic / pathology. Photosensitizing Agents / therapeutic use

MedlinePlus Health Information. consumer health - Autoimmune Diseases.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17973045.001).

[ISSN] 1474-905X

[Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology

[ISO-abbreviation] Photochem. Photobiol. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Currently, Arsenic Trioxide (ATO) is considered the treatment of choice for patients with relapsed acute promyelocytic leukemia (APL).

Recently, a durable remission with minimal toxicity by single agent ATO or ATO + ATRA in newly diagnosed APL was reported by different groups.

These regimens have minimal toxicity and can be administered on an outpatient basis after remission induction, thus they could become a real, less toxic and more economic option to ATRA + anthracyclines in particular in low risk APL, or in patients that cannot undergo chemotherapy because of age or comorbid conditions and in patients that refuse chemotherapy.

Significantly, these therapies are a successful attempt to cure a tumoral disease without chemotherapy.

The results of clinical trials of ATO administration as single agent in multiple myeloma (MM) and myelodisplastic syndromes (MDS) were encouraging and showed clinical effects but they were not close to APL success.

On the contrary, results of clinical trials to treat non-APL acute myeloid leukemia (AML) were disappointing.

We suggest that a combination therapy with drugs targeting specific pro-survival molecules or capable to enhance pro-apoptotic pathways may lead to an improvement of ATO efficacy against hematological malignancies, in particular AML.

Our pre-clinical studies showed that ATO is capable to induce cell death in acute leukemia cells but the apoptotic function is limited since it can induce also a mechanism of cell defense by activating pro-survival molecules such as MEK-ERK, Bcl-xL, Bcl-2.

By combining ATO with specific MEK inhibitors, we demonstrated that the block of MEK-ERK phosphorylation, the induction of Bad de-phosphorylation, and activation of p53AIP1 apoptotic pathway interrupt the pro-survival mechanisms of ATO and kill the leukemic cells by apoptotic synergism.

Our results provide an experimental basis for combined or sequential treatment with MEK inhibitors and ATO in AML.

[MeSH-major] Arsenicals / therapeutic use. Clinical Trials as Topic / trends. Hematologic Neoplasms / drug therapy. Multiple Myeloma / drug therapy. Oxides / therapeutic use

MedlinePlus Health Information. consumer health - Clinical Trials.

MedlinePlus Health Information. consumer health - Multiple Myeloma.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17168655.001).

[ISSN] 1873-4316

[Journal-full-title] Current pharmaceutical biotechnology

[ISO-abbreviation] Curr Pharm Biotechnol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

[Number-of-references] 62

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This study was purposed to explore the inhibitory effect of Curcumin on growth of retinoic acid-resistant acute promyelocytic leukemia (APL) cells and its mechanism.

The NB4-R1, an APL cell line resistant to retinoic acid, was used as a model.

The growth level of NB4-R1 was detected by MTT assay, the morphologic features of cells were observed by light microscopy, the mitochondrial transmembrane potential was determined by flow cytometry, the expressions of apoptosis-related proteins procaspase 3, caspase 3, PARP and BCL-XL were measured by Western blot.

The morphologic observation showed existence of apoptotic bodies in NB4-R1 cells treated with 20 micromol/L of Curcumin.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. CURCUMIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20416164.001).

[ISSN] 1009-2137

[Journal-full-title] Zhongguo shi yan xue ye xue za zhi

[ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi

[Language] CHI

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; 5688UTC01R / Tretinoin; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; IT942ZTH98 / Curcumin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice.

Antiphospholipid (aPL) antibodies bind to beta2glycoprotein I (beta2GPI) and cause endothelial cell (EC) activation and thrombosis in mice. beta2GPI binds to EC through its Vth domain and induces their activation.

TIFI is a 20 amino acid synthetic peptide that shares similarity with the Vth domain of beta2GPI.

Our objectives were to examine the ability of TIFI to affect aPL-mediated thrombosis in mice and the interactions of TIFI, beta2GPI with phospholipid surfaces and target cells.

CD1 mice were injected with IgG from a patient with antiphospholipid syndrome (IgG-APS) or with control IgG-NHS and with either TIFI or with control peptide (VITT).

Inhibition and competition studies were done using aPL antibodies, cardiolipin (CL) liposomes in the presence of varying amounts of TIFI and beta2GPI.

TIFI reverted the beta2GPI-dependent binding of aPL antibodies to CL liposomes in a dose-dependent fashion.

This effect was abrogated by addition of beta2GPI, suggesting that TIFI displaces the binding of beta2GPI to phospholipids.

The data indicate that TIFI abrogates thrombogenic properties of aPL in mice by competing with beta2GPI and preventing its binding to target cells.

[MeSH-major] Antiphospholipid Syndrome / immunology. Fibrinolytic Agents / therapeutic use. Peptides / therapeutic use. Thrombosis / prevention & control. beta 2-Glycoprotein I / chemistry

[MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Antiphospholipid / blood. Antibodies, Antiphospholipid / immunology. Antibodies, Antiphospholipid / toxicity. Binding, Competitive. Cardiolipins / immunology. Cells, Cultured. Endothelium, Vascular / drug effects. Endothelium, Vascular / physiopathology. Enzyme-Linked Immunosorbent Assay. Humans. Immunoglobulin G / toxicity. Liposomes. Macrophages / drug effects. Macrophages / immunology. Male. Mice. Molecular Mimicry. Molecular Sequence Data. Neutralization Tests. Protein Binding / drug effects. Protein Structure, Tertiary

Genetic Alliance. consumer health - Thrombosis.

MedlinePlus Health Information. consumer health - Blood Clots.

COS Scholar Universe. author profiles.

Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16830882.001).

[ISSN] 0961-2033

[Journal-full-title] Lupus

[ISO-abbreviation] Lupus

[Language] eng

[Grant] United States / NCRR NIH HHS / RR / G12-RR03034; United States / NIGMS NIH HHS / GM / S02GM08248

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Cardiolipins; 0 / Fibrinolytic Agents; 0 / Immunoglobulin G; 0 / Liposomes; 0 / Peptides; 0 / TIFI peptide; 0 / beta 2-Glycoprotein I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages.

CONTEXT: Anti-phospholipid antibodies (aPL) are a heterogeneous group of autoantibodies, the presence of which is associated with thrombotic events and miscarriage.

OBJECTIVE: To establish whether antibodies directed against phospholipid-binding plasma proteins such as beta(2)-glycoprotein I (beta(2)GPI), prothrombin (PT), and annexin V (Anx V) constitute a risk factor for thromboembolism in patients with systemic lupus erythematosus (SLE) and for miscarriage in women with recurrent pregnancy loss (RPL), independently of the presence of the classic anticardiolipin (aCL) antibodies, and whether their determination together with that of aCL would help to increase the diagnostic sensitivity of aPL tests.

DESIGN: The prevalence of various antibodies directed toward phospholipids (CL and other anionic phospholipids [APL]) and phospholipid-binding proteins (beta(2)GPI, PT, and Anx V) was determined by immunoenzymatic methods in 311 serum samples.

PATIENTS: Twenty-five patients with aCL-positive primary anti-phospholipid syndrome (pAPS); 89 patients with SLE, 23 of whom had thrombotic complications (SLE/APS) and 66 of whom had no thrombosis; and 77 women with unexplained recurrent pregnancy loss comprised our study group.

RESULTS: Immunoglobulin (Ig) G and/or IgM aAPL, anti-beta(2)GPI, anti-PT, and IgG anti-Anx V antibodies were detected in 25 (100%), 20 (80%), 15 (60%), and 6 (24%), respectively, of the 25 aCL-positive pAPS patients; IgG and/or IgM aCL, aAPL, anti-beta(2)GPI, anti-PT, and IgG anti-Anx V antibodies were detected in 33 (37%), 42 (47%), 31 (35%), 40 (45%), and 12 (13%) of the 89 SLE patients, respectively.

Of the 56 SLE patients who proved to be aCL negative, anti-beta(2)GPI was present in 3 patients (5%), anti-PT in 13 (23%) patients, and anti-Anx V in 5 (9%) patients.

In the subset of 23 SLE/APS patients, IgG anti-PT prevalence was higher than that of the other autoantibodies (87% vs 70% aCL, 66% aAPL, 57% anti-beta(2)GPI, and 4% anti-Anx V), and in 26% of cases, IgG anti-PT was the only antibody present.

Anti-PT had a slightly lower specificity than aCL (46% vs 49%); however, the occurrence of both antibodies brought the specificity to 92.4%.

The highest risk for thrombosis in SLE patients was associated with the presence of IgG anti-PT antibody (odds ratio [OR] 15.3, P < .001, vs 6.5 aCL, 3.5 aAPL, 3.4 anti-beta(2)GPI, 0.2 anti-Anx V).

Fifty-one of the 77 women with recurrent pregnancy loss were negative for all antibodies investigated; the prevalence of IgG and/or IgM aCL, aAPL, anti-beta(2)GPI, anti-PT, and IgG anti-Anx V antibodies was 6% (5), 12% (9), 6% (5), 16% (12), and 17% (13), respectively.

Of the 67 aCL-negative women, none had anti-beta(2)GPI antibodies, 7 (11%) were anti-PT positive, and 13 (19%) were anti-Anx V positive.

In the subgroup of 26 recurrent pregnancy loss patients who had at least one antibody, anti-Anx V was present in 50% of cases (in 42% as the sole antibody) and was the only antibody significantly associated with miscarriage (P = .02).

CONCLUSIONS: The results of this study indicate that it is useful to measure anti-PT antibodies in addition to the more widely used aCL and anti-beta(2)GPI antibodies in the prognostic evaluation of SLE patients for the risk of thrombosis, and the results also confirm that anti-Anx V antibodies may play an important role in recurrent pregnancy loss.

[MeSH-major] Abortion, Spontaneous / blood. Antibodies, Anticardiolipin / blood. Antibodies, Antiphospholipid / blood. Antiphospholipid Syndrome / blood. Lupus Erythematosus, Systemic / blood

[MeSH-minor] Adult. Annexin A5 / blood. Annexin A5 / immunology. Autoantibodies / blood. Cardiolipins / immunology. Enzyme-Linked Immunosorbent Assay / methods. Female. Glycoproteins / blood. Glycoproteins / immunology. Humans. Male. Middle Aged. Phospholipids / immunology. Pregnancy. Prevalence. Prothrombin / immunology. Thromboembolism / etiology. beta 2-Glycoprotein I

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Lupus.

MedlinePlus Health Information. consumer health - Miscarriage.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15628909.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Annexin A5; 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Cardiolipins; 0 / Glycoproteins; 0 / Phospholipids; 0 / beta 2-Glycoprotein I; 9001-26-7 / Prothrombin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical relevance of the recent update of the classification criteria for definite antiphospholipid syndrome: an obstetric medicine clinic series of 107 patients.

[MeSH-major] Antiphospholipid Syndrome / classification. Antiphospholipid Syndrome / diagnosis

[MeSH-minor] Antibodies, Antiphospholipid / blood. Female. Humans. Lupus Coagulation Inhibitor / blood. Partial Thromboplastin Time. Phospholipids / chemistry. Pregnancy. Pregnancy Complications / classification. Pregnancy Complications / diagnosis. Pregnancy Complications / immunology. Prognosis. Retrospective Studies

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]

(PMID = 16869832.001).

[ISSN] 1538-7933

[Journal-full-title] Journal of thrombosis and haemostasis : JTH

[ISO-abbreviation] J. Thromb. Haemost.

[Language] eng

[Publication-type] Comment; Letter

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Lupus Coagulation Inhibitor; 0 / Phospholipids

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TCR ligand avidity determines the mode of B-Raf/Raf-1/ERK activation leading to the activation of human CD4+ T cell clone.

The interactions between peptide/MHC complexes and their cognate TCR are essential for various T cell responses.

However, the relationship between the avidity of TCR ligand and the subsequent intracellular signaling through the TCR is still unclear.

To investigate the effects of TCR ligand avidity on TCR-mediated signaling, we established L cells expressing HLA-DR4 molecules covalently linked with agonistic peptide (high-affinity ligand) or altered peptide ligand (APL; low-affinity ligand) at various densities as APC for a cognate human CD4(+) T cell clone.

Using this system, we demonstrated that the T cell clone stimulated with APL/HLA-DR4 complexes presented at an excessive density provoked the up-regulation of CD69, IL-2 production and proliferation, but no detectable phosphorylation of ZAP-70/LAT/SLP-76.

The strength and duration of B-Raf/ERK activations closely correlated with the density of the TCR ligand.

A knockdown approach confirmed that B-Raf activation was indispensable for the APL-induced T cell responses.

These observations suggest that the differences in TCR-peptide/MHC interactions reflect the strength and duration of B-Raf/Raf-1/ERK activation in the human CD4(+) T cells.

[MeSH-minor] Amino Acid Sequence. Animals. Aotidae. Cell Transformation, Viral. Cells, Cultured. Clone Cells. Enzyme Activation / immunology. HLA-DR4 Antigen / physiology. Herpesvirus 2, Saimiriine. Humans. Jurkat Cells. L Cells (Cell Line). Ligands. Mice. Mice, Inbred C57BL. Molecular Sequence Data. NIH 3T3 Cells. PC12 Cells. Rats

COS Scholar Universe. author profiles.

Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

National BioResource Project. culture/stock collections - NBRP resources .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16791876.001).

[ISSN] 0014-2980

[Journal-full-title] European journal of immunology

[ISO-abbreviation] Eur. J. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / HLA-DR4 Antigen; 0 / Ligands; 0 / Receptors, Antigen, T-Cell; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We have shown earlier that IFNgamma and As2O3 act synergistically in acute promyelocytic leukemia cells to upregulate IRF-1 expression and to induce apoptosis.

Here, we show that in the human fibrosarcoma cell line 2fTGH, As2O3 prolongs IFNgamma-induced STAT1 phosphorylation resulting in persistent binding of STAT1 to GAS motif leading to an increase in IRF-1 expression which correlated with both higher anti-proliferative effect and increased apoptosis.

MedlinePlus Health Information. consumer health - Arsenic.

Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16914093.001).

[ISSN] 1165-158X

[Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)

[ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

[Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GAS1 protein, human; 0 / GPI-Linked Proteins; 0 / Growth Inhibitors; 0 / Interferon Regulatory Factor-1; 0 / Membrane Proteins; 0 / STAT1 Transcription Factor; 82115-62-6 / Interferon-gamma; N712M78A8G / Arsenic

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Kikuchi's lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome.

Kikuchi-Fujimoto disease is a form of reactive lymphadenopathy, which was firstly described in Japan, but is uncommon in the Western world.

We retrospectively reviewed the medical records of nine cases of adult or adolescent Kikuchi's disease diagnosed in a single Haematology Unit in Athens, Greece between 1990 and 2006.

The median leukocyte count was 4.7 x 10(9)/l (2.2-4.9) with a normal differential in 7/9 patients.

One patient had clinical and laboratory evidence of primary antiphospholipid syndrome (APLS).

In conclusion, Kikuchi's disease represents a rare but important diagnostic possibility for patients presenting with lymphadenopathy in Greece and other western countries.

[MeSH-major] Antiphospholipid Syndrome / diagnosis. Antiphospholipid Syndrome / physiopathology. Histiocytic Necrotizing Lymphadenitis / diagnosis. Histiocytic Necrotizing Lymphadenitis / physiopathology

[MeSH-minor] Adolescent. Adult. Antibodies, Antiphospholipid / analysis. Antibodies, Antiphospholipid / blood. Autoimmune Diseases / diagnosis. Autoimmune Diseases / epidemiology. Autoimmune Diseases / physiopathology. Comorbidity. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Greece. Humans. Leukocyte Count. Lymph Nodes / pathology. Male. Prevalence. Spleen / pathology. Spleen / physiopathology. Splenomegaly / diagnosis. Splenomegaly / epidemiology. Splenomegaly / physiopathology. Young Adult

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Diagn Cytopathol. 2001 Oct;25(4):220-4 [11599104.001]

[Cites] Am J Surg Pathol. 1995 Jul;19(7):798-809 [7793478.001]

[Cites] Clin Rheumatol. 1991 Mar;10(1):90-3 [2065516.001]

[Cites] Ann Hematol. 2002 Dec;81(12):732-5 [12483371.001]

[Cites] J Microbiol Immunol Infect. 2005 Feb;38(1):35-40 [15692625.001]

[Cites] N Engl J Med. 2002 Mar 7;346(10):752-63 [11882732.001]

[Cites] In Vivo. 2002 Sep-Oct;16(5):311-6 [12494869.001]

[Cites] Lupus. 1994 Oct;3(5):409-11 [7841995.001]

[Cites] Pathol Int. 2003 Apr;53(4):221-6 [12675765.001]

[Cites] Semin Diagn Pathol. 1988 Nov;5(4):329-45 [3217625.001]

[Cites] Am J Clin Pathol. 2004 Jul;122(1):141-52 [15272543.001]

[Cites] Arch Pathol Lab Med. 1985 Feb;109(2):107-8 [3883942.001]

[Cites] Lupus. 2005;14(12):967-9 [16425578.001]

[Cites] Medicine (Baltimore). 2000 Sep;79(5):338-47 [11039082.001]

[Cites] Rheumatol Int. 2005 May;25(4):303-6 [15645234.001]

[Cites] Clin Rheumatol. 2005 Feb;24(1):60-3 [15517448.001]

[Cites] Am J Med. 1996 Oct;101(4):401-5 [8873511.001]

[Cites] Lupus. 2001;10(2):126-8 [11237125.001]

[Cites] Semin Oncol. 1993 Dec;20(6):570-82 [8296196.001]

[Cites] In Vivo. 2003 Jan-Feb;17(1):51-3 [12655790.001]

(PMID = 19693507.001).

[ISSN] 1437-160X

[Journal-full-title] Rheumatology international

[ISO-abbreviation] Rheumatol. Int.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Thromboembolic and bleeding complications in acute leukemia.

The risk of both thromboembolic and bleeding complications is high in acute leukemia.

This double hazard has a significant negative impact on the morbidity and mortality of patients with this disease.

The clinical manifestations of both complications show special features specific to the form of acute leukemia.

Recognition of these characteristics is important in the diagnosis and management of acute leukemia.

In this article, several additional issues are addressed, including the features of bleeding and thrombosis in acute promyelocytic leukemia, the current understanding of the leukostasis syndrome and the iatrogenic complications including catheter-associated thrombosis, and the adverse effects of therapeutic agents used in acute leukemia.

[MeSH-major] Hemorrhage / etiology. Leukemia / complications. Thromboembolism / etiology

[MeSH-minor] Acute Disease. Blood Vessels / pathology. Drug-Related Side Effects and Adverse Reactions. Humans. Thrombophilia. Thrombosis / complications. Thrombosis / epidemiology

MedlinePlus Health Information. consumer health - Bleeding.

MedlinePlus Health Information. consumer health - Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21091148.001).

[ISSN] 1747-4094

[Journal-full-title] Expert review of hematology

[ISO-abbreviation] Expert Rev Hematol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We saw a 34-year-old pregnant woman with acute promyelocytic leukemia, who developed acute respiratory failure from all-trans-retinoic acid (ATRA) syndrome.

She was discharged from the intensive care unit after 12 days.

[MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Respiration, Artificial. Respiratory Insufficiency / chemically induced. Tretinoin / adverse effects

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Respiratory Failure.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19558746.001).

[ISSN] 0020-1324

[Journal-full-title] Respiratory care

[ISO-abbreviation] Respir Care

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations].

Antiphospholipid antibodies (aPL) represent a heterogeneous group of antibodies that recognize various antigenic targets including beta2 glycoprotein I (beta2GPI), prothrombin (PT), activated protein C, tissue plasminogen activator, plasmin and annexin A2.

The most commonly used tests to detect aPL are: lupus anticoagulant (LAC), a functional coagulation assay, anticardiolipin antibody (aCL) and anti-beta2GPI antibody (anti-beta2GPI), which are enzyme-linked immunoassay (ELISA).

Clinically aPL are associated with thrombosis and/or with pregnancy morbidity.

Apparently aPL alone are unable to induce thrombotic manifestations, but they increase the risk of vascular events that can occur in the presence of another thrombophilic condition; on the other hand obstetrical manifestations were shown to be associated not only to thrombosis but mainly to a direct antibody effect on the trophoblast.

[MeSH-major] Antibodies, Anticardiolipin. Antibodies, Antiphospholipid. Antiphospholipid Syndrome. Lupus Coagulation Inhibitor. Pregnancy Complications. Thrombosis / immunology

MedlinePlus Health Information. consumer health - Blood Clots.

MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20390120.001).

[ISSN] 0048-7449

[Journal-full-title] Reumatismo

[ISO-abbreviation] Reumatismo

[Language] ita

[Publication-type] Comparative Study; English Abstract; Journal Article; Review

[Publication-country] Italy

[Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I

[Number-of-references] 69

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Laboratory findings, 7 days postoperatively, showed high levels of immunoglobulin G anticardiolipin antibody.

This case does not match the criteria for antiphospholipid syndrome, but some English-language reports have shown rising antiphospholipid antibody levels, particularly anticardiolipin antibodies, in patients with neoplasm.

In those cases, levels have normalized after successful therapy.

Antiphospholipid antibody levels should be examined before surgery to identify risks of hypercoagulability.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20049910.001).

[ISSN] 1098-2752

[Journal-full-title] Microsurgery

[ISO-abbreviation] Microsurgery

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Anticardiolipin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Thrombophilias and peripheral arterial occlusive disease].

Peripheral arterial occlusive disease is a frequent disease due to the classical vascular risk factors such as smoking, diabetes mellitus, dyslipidemia, and hypertension.

Despite these risk factors, many thrombophilias (physiological inhibitors defects, Factor V Leiden and 20210A prothrombin gene variant, antiphospholipid antibodies, mild hyperhomocysteinemia 15-30micromol/l) can be evoked in some clinical forms of peripheral arterial occlusive disease.

Screening for these thrombophilias is justified in patients with venous thromboembolic disease, or signs of antiphospholipid syndrome and possibly in different situations such as premature atheroma of lower limbs, chronic ischaemia, evolutive disease despite adapted treatment and revascularisation failures without evident technical explanation.

Except for the antiphospholipid syndrome, there is currently no consensus for systematic screening of thrombophilia and treatment in patients with peripheral arterial occlusive disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18554834.001).

[ISSN] 0398-0499

[Journal-full-title] Journal des maladies vasculaires

[ISO-abbreviation] J Mal Vasc

[Language] fre

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] France

[Chemical-registry-number] 0 / Antithrombins; 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin

[Number-of-references] 62

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Acute myocardial infarction with variable clinical manifestations: probable catastrophic primary antiphospholipid antibody syndrome: a case report].

A 62-year-old diabetic man was admitted to our hospital because of acute myocardial infarction.

Emergent coronary angiography showed multiple thromboembolic occlusions in the distal circumflex and anterior descending arteries.

These clinical manifestations and laboratory findings suggested catastrophic antiphospholipid antibody syndrome.

Acute myocardial infarction is rare as the initial manifestation of catastrophic antiphospholipid antibody syndrome.

[MeSH-major] Antiphospholipid Syndrome / complications. Myocardial Infarction / etiology

[MeSH-minor] Anticoagulants / therapeutic use. Coronary Angiography. Diabetic Retinopathy / complications. Diagnosis, Differential. Humans. Kidney Diseases / complications. Male. Middle Aged. Prognosis

Genetic Alliance. consumer health - Catastrophic Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

MedlinePlus Health Information. consumer health - Heart Attack.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16252568.001).

[ISSN] 0914-5087

[Journal-full-title] Journal of cardiology

[ISO-abbreviation] J Cardiol

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Anticoagulants

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Hyperhomocysteine like thrombocytic risk factor in patient with systemic lupus erythematous with antiphospholipid syndrome].

[Transliterated title] Hiperhomocisteinemia como factor de riesgo trombótico en pacientes con lupus eritematoso sistémico y síndrome antifosfolípido.

OBJECTIVES: to detect the prevalence of hyperhcy in SLE patients with and without antiphospholipid syndrom; to compare the Hcy levels between those patients and healthy controls and to determine the correlation between hyperhcy and antiphospholipid antibodies.

PATIENTS AND METHODS: we studied 44 SLE patients: 17 had antiphospholipid syndrom and 27 didn't have it, and we compared them to 24 healthy controls.

Hyperhcy was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom.

15(75%) of them had hiperhcy.

[MeSH-major] Antiphospholipid Syndrome / physiopathology. Hyperhomocysteinemia / complications. Lupus Erythematosus, Systemic / physiopathology. Thrombosis / etiology

[MeSH-minor] Adult. Aged. Antibodies, Antiphospholipid / blood. Argentina. Female. Homocysteine / blood. Humans. Male. Middle Aged. Risk Factors. Venous Thrombosis / blood

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

MedlinePlus Health Information. consumer health - Blood Clots.

MedlinePlus Health Information. consumer health - Lupus.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16281418.001).

[ISSN] 0014-6722

[Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)

[ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Argentina

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0LVT1QZ0BA / Homocysteine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The analogs were examined for their antiproliferative activity in vitro against human breast cancer cells (MCF-7) and promyelocytic leukemia (HL-60) cells.

The studies of calcemic activity in vivo showed that analogs PRI-2208 and PRI-2209 did not influence the serum calcium level in doses, in which 1alpha,25(OH)2D3 or (24R)-1,24(OH)2D3 significantly increased this level.

Hazardous Substances Data Bank. CHOLECALCIFEROL .

Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.

(PMID = 20227499.001).

[ISSN] 1879-1220

[Journal-full-title] The Journal of steroid biochemistry and molecular biology

[ISO-abbreviation] J. Steroid Biochem. Mol. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 1C6V77QF41 / Cholecalciferol; SY7Q814VUP / Calcium

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We have identified an intergenic transcriptional activity that is located between the human HOXA1 and HOXA2 genes, shows myeloid-specific expression, and is up-regulated during granulocytic differentiation.

The novel gene, termed HOTAIRM1 (HOX antisense intergenic RNA myeloid 1), is transcribed antisense to the HOXA genes and originates from the same CpG island that embeds the start site of HOXA1.

HOTAIRM1 is the most prominent intergenic transcript expressed and up-regulated during induced granulocytic differentiation of NB4 promyelocytic leukemia and normal human hematopoietic cells; its expression is specific to the myeloid lineage.

Its induction during retinoic acid (RA)-driven granulocytic differentiation is through RA receptor and may depend on the expression of myeloid cell development factors targeted by RA signaling.

Knockdown of HOTAIRM1 quantitatively blunted RA-induced expression of HOXA1 and HOXA4 during the myeloid differentiation of NB4 cells, and selectively attenuated induction of transcripts for the myeloid differentiation genes CD11b and CD18, but did not noticeably impact the more distal HOXA genes.

COS Scholar Universe. author profiles.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

SciCrunch. HGNC: Data: Gene Annotation .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Cancer Res Clin Oncol. 2000 Jan;126(1):33-40 [10641747.001]

[Cites] Leukemia. 2000 Feb;14(2):255-61 [10673742.001]

[Cites] Transfusion. 2000 Dec;40(12):1475-81 [11134567.001]

[Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]

[Cites] Blood. 2003 Feb 15;101(4):1558-65 [12560242.001]

[Cites] J Cell Biochem. 2003 Jul 1;89(4):848-61 [12858349.001]

[Cites] J Biol Chem. 2003 Nov 28;278(48):47792-802 [14512427.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14603-6 [14638945.001]

[Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]

[Cites] J Leukoc Biol. 2004 Feb;75(2):358-72 [14634056.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2446-51 [14983029.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6508-13 [15096607.001]

[Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W130-4 [15215365.001]

[Cites] Proc Natl Acad Sci U S A. 1980 Sep;77(9):5201-5 [6159641.001]

[Cites] J Leukoc Biol. 1985 Aug;38(2):341-50 [3861749.001]

[Cites] Mech Dev. 1992 Sep;38(3):217-27 [1360810.001]

[Cites] Blood. 1993 Dec 15;82(12):3592-9 [8260698.001]

[Cites] J Clin Invest. 1999 May 15;103(10):1399-408 [10330422.001]

[Cites] Methods Enzymol. 1999;303:272-97 [10349650.001]

[Cites] Exp Hematol. 1999 Sep;27(9):1355-67 [10480426.001]

[Cites] Science. 2004 Dec 24;306(5705):2242-6 [15539566.001]

[Cites] J Exp Zool B Mol Dev Evol. 2005 Jan 15;304(1):75-85 [15643628.001]

[Cites] Mol Cell. 2005 Mar 4;17(5):683-94 [15749018.001]

[Cites] FEBS Lett. 2005 Mar 21;579(8):1795-801 [15763554.001]

[Cites] J Biol Chem. 2005 Apr 1;280(13):12359-70 [15681849.001]

[Cites] Trends Immunol. 2005 Jul;26(7):388-95 [15922663.001]

[Cites] PLoS Biol. 2005 Aug;3(8):e254 [16089502.001]

[Cites] Exp Hematol. 2005 Sep;33(9):1055-61 [16140154.001]

[Cites] BMC Genomics. 2005;6:104 [16083503.001]

[Cites] Nature. 2005 Oct 13;437(7061):1032-7 [16136080.001]

[Cites] Cancer Res. 2005 Oct 15;65(20):9245-52 [16230385.001]

[Cites] Blood. 2005 Dec 1;106(12):3988-94 [16091451.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19081-6 [16357205.001]

[Cites] Curr Opin Hematol. 2006 Mar;13(2):67-73 [16456371.001]

[Cites] Nat Rev Mol Cell Biol. 2006 Aug;7(8):612-6 [16723972.001]

[Cites] Science. 2006 Sep 29;313(5795):1918-22 [17008523.001]

[Cites] Leuk Res. 2007 Jan;31(1):49-57 [16764927.001]

[Cites] PLoS Genet. 2006 Oct 13;2(10):e171 [17040132.001]

[Cites] RNA. 2007 Feb;13(2):223-39 [17185360.001]

[Cites] Gene. 2007 Apr 15;391(1-2):223-32 [17303350.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]

[Cites] J Clin Invest. 2007 Apr;117(4):865-8 [17404613.001]

[Cites] PLoS One. 2007;2(4):e356 [17406680.001]

[Cites] Biochem Biophys Res Commun. 2007 Jun 8;357(3):724-30 [17445766.001]

[Cites] J Biol Chem. 2007 Jun 8;282(23):16846-59 [17439948.001]

[Cites] Blood. 2007 Jun 15;109(12):5191-8 [17351112.001]

[Cites] Genome Res. 2007 Jun;17(6):886-97 [17119069.001]

[Cites] Oncogene. 2007 Jun 14;26(28):4115-23 [17213805.001]

[Cites] Nature. 2007 Jun 14;447(7146):799-816 [17571346.001]

[Cites] Cell. 2007 Jun 29;129(7):1311-23 [17604720.001]

[Cites] Blood. 2007 Jul 15;110(2):640-50 [17420285.001]

[Cites] Cell. 2007 Jul 13;130(1):77-88 [17632057.001]

[Cites] PLoS One. 2007;2(7):e630 [17637845.001]

[Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]

[Cites] Oncogene. 2007 Oct 15;26(47):6766-76 [17934484.001]

[Cites] Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H29-40 [17982008.001]

[Cites] PLoS Genet. 2007 Nov;3(11):e212 [18039033.001]

(PMID = 19144990.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NHGRI NIH HHS / HG / U01 HG003147; United States / NIDDK NIH HHS / DK / R01 DK054369; United States / NIDDK NIH HHS / DK / DK54369; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NHGRI NIH HHS / HG / U01-HG003147

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Intergenic; 0 / HOXA2 protein, human; 0 / Homeodomain Proteins; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / Regulatory Sequences, Ribonucleic Acid; 0 / Transcription Factors; 0 / homeobox A1 protein; 0 / long non-coding RNA HOTAIRM1, human; 157907-48-7 / HoxA protein; EC 2.7.7.- / RNA Polymerase II

[Other-IDs] NLM/ PMC2656274

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We reported previously that sequestration of MRE11/RAD50/NBS1 complexes represses ALT-mediated telomere length maintenance, and suppresses formation of ALT-associated promyelocytic leukemia (PML) bodies (APBs).

APBs are PML bodies containing telomeric DNA and telomere-binding proteins, and are observed only in a small fraction of cells within asynchronously dividing ALT-positive cell populations.

We combined methionine restriction with RNA interference to test whether the following proteins are required for APB formation: PML body-associated proteins, PML and Sp100; telomere-associated proteins, TRF1, TRF2, TIN2 and RAP1; and DNA repair proteins, MRE11, RAD50, NBS1 and 53BP1.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17297460.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Autoantigens; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / MRE11A protein, human; 0 / NBN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / Rad50 protein, human; 0 / TINF2 protein, human; 0 / TP53BP1 protein, human; 0 / Telomere-Binding Proteins; 0 / Telomeric Repeat Binding Protein 1; 0 / Telomeric Repeat Binding Protein 2; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 135844-47-2 / Sp100 protein, human; 143220-95-5 / PML protein, human; AE28F7PNPL / Methionine; EC 6.5.1.- / DNA Repair Enzymes

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of carrier stiffness and microtopology on two-dimensional kinetics of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) interactions.

Interactions of P-selectin with P-selectin glycoprotein ligand-1 (PSGL-1) were used to demonstrate such effects by presenting the molecules on three carrier systems: human red blood cells (RBCs), human promyelocytic leukemia HL-60 cells, and polystyrene beads.

These results demonstrate that the carrier stiffness and microtopology of a receptor influences its rate of encountering and binding a surface ligand but does not subsequently affect the stability of binding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17267403.001).

[ISSN] 0021-9258

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / P-Selectin; 0 / P-selectin ligand protein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anticardiolipin and anti-beta-2-glycoprotein I antibodies.

The anticardiolipin (aCL) antibody test was first established in 1983, using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase immunoassAy.

The wide use of this test was determinant in the definition of the "aCL or antiphospholipid syndrome" (APS).Later, it was demonstrated that aCL antibodies do not recognize anionic phospholipids but are directed against plasma proteins bound to anionic phospholipids, mainly beta-2-glycoprotein I, which is now considered as the autoantigen in APS.

Anti-beta-2-glycoprotein I (anti-beta2GPI) is not yet accepted as a serological criterion for APS, but most investigators would consider a patient with anti-beta2GPI antibodies and clinical features of APS to have the syndrome. aCL and anti-beta2GPI are a heterogeneous group of antibodies with different clinical significances and can be present in different autoimmune diseases as well as in infectious diseases.

[MeSH-major] Antibodies, Anticardiolipin / blood. Antibodies, Antiphospholipid / blood. Glycoproteins / immunology

[MeSH-minor] Antiphospholipid Syndrome / diagnosis. Antiphospholipid Syndrome / immunology. Autoimmune Diseases / immunology. Female. History, 20th Century. Humans. Pregnancy. beta 2-Glycoprotein I

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15804703.001).

[ISSN] 0891-6934

[Journal-full-title] Autoimmunity

[ISO-abbreviation] Autoimmunity

[Language] eng

[Publication-type] Historical Article; Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Antibodies, Antiphospholipid; 0 / Glycoproteins; 0 / beta 2-Glycoprotein I

[Number-of-references] 60

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Transliterated title] Anomalies de l'hemostase dans l'infarctus du myocarde sur coronaires angiographiquement saines: a propos de 39 cas.

Myocardial infarction with normal coronary artery is ussually inaugural, with electric and clinical characteristics similar to those with atheroma.

They were 33 males and 6 females aged between 22 and 75 years (44 + 13 years), in whom the deficiency in protein C and S. antithrombin, activated protein C resistance and antiphospholipid antibodies were assessed.

RESULTS: Concurrent abnormalities of haemostasis were found in 10 patients: Antiphospholipid antibodies, found in 5 patients constitute the most frequent abnormality.

[MeSH-major] Blood Coagulation Disorders / diagnosis. Coronary Angiography. Myocardial Infarction / blood

[MeSH-minor] Activated Protein C Resistance / diagnosis. Adult. Aged. Antibodies, Antiphospholipid / blood. Antithrombins / analysis. Antithrombins / deficiency. Coronary Vessels / pathology. Female. Humans. Immunoglobulin G / blood. Male. Middle Aged. Protein C / analysis. Protein C Deficiency / diagnosis. Protein S / analysis. Protein S Deficiency / diagnosis. Retrospective Studies

MedlinePlus Health Information. consumer health - Bleeding Disorders.

MedlinePlus Health Information. consumer health - Heart Attack.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16422365.001).

[ISSN] 0041-4131

[Journal-full-title] La Tunisie médicale

[ISO-abbreviation] Tunis Med

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] Tunisia

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antithrombins; 0 / Immunoglobulin G; 0 / Protein C; 0 / Protein S

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.

The use of "altered peptide ligands" (APL), epitopes designed for exerting increased immunogenicity as compared with native determinants, represents nowadays one of the most utilized strategies for overcoming immune tolerance to self-antigens and boosting anti-tumor T cell-mediated immune responses.

However, the actual ability of APL-primed T cells to cross-recognize natural epitopes expressed by tumor cells remains a crucial concern.

In the present study, we show that CAP1-6D, a superagonist analogue of a carcinoembriyonic antigen (CEA)-derived HLA-A*0201-restricted epitope widely used in clinical setting, reproducibly promotes the generation of low-affinity CD8(+) T cells lacking the ability to recognized CEA-expressing colorectal carcinoma (CRC) cells.

Short-term T cell cultures, obtained by priming peripheral blood mononuclear cells from HLA-A*0201(+) healthy donors or CRC patients with CAP1-6D, were indeed found to heterogeneously cross-react with saturating concentrations of the native peptide CAP1, but to fail constantly lysing or recognizing through IFN- gamma release CEA(+)CRC cells.

Characterization of anti-CAP1-6D T cell avidity, gained through peptide titration, CD8-dependency assay, and staining with mutated tetramers (D227K/T228A), revealed that anti-CAP1-6D T cells exerted a differential interaction with the two CEA epitopes, i.e., displaying high affinity/CD8-independency toward the APL and low affinity/CD8-dependency toward the native CAP1 peptide.

Our data demonstrate that the efficient detection of self-antigen expressed by tumors could be a feature of high avidity CD8-independent T cells, and underline the need for extensive analysis of tumor cross-recognition prior to any clinical usage of APL as anti-cancer vaccines.

[MeSH-minor] Antibody Affinity. Antigens, Neoplasm / chemistry. Cancer Vaccines. Colorectal Neoplasms / metabolism. Epitopes / chemistry. HLA-A Antigens / chemistry. HLA-A2 Antigen. Immunotherapy / methods. Leukocytes, Mononuclear / metabolism. Ligands. Peptides / chemistry. Risk. T-Lymphocytes / metabolism

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17564703.001).

[ISSN] 0340-7004

[Journal-full-title] Cancer immunology, immunotherapy : CII

[ISO-abbreviation] Cancer Immunol. Immunother.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CAP1-6D; 0 / Cancer Vaccines; 0 / Epitopes; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Ligands; 0 / Oligopeptides; 0 / Peptides; 0 / Receptors, Antigen, T-Cell

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.

The recently identified retinoic acid (RA)-metabolizing cytochrome P450RAI-1 (CYP26A1) has been implicated in accelerated metabolism and rapid clearance of all-trans-retinoic acid (ATRA) during prolonged oral administration in patients with acute promyelocytic leukemia (APL), leading to a progressive decline in plasma drug levels.

We studied induction and regulation of CYP26A1 expression and ATRA metabolism in human intestinal (Caco-2), liver (HepG2), endothelial (HUVEC), and APL (NB4) cell lines.

A specific RA receptor-alpha antagonist totally inhibited ATRA-induced expression of CYP26A1, indicating that RA receptor-alpha plays a major role in CYP26A1 expression in HepG2 cells.

Our data suggest that upregulation of CYP26A1 expression in intestinal, endothelial, liver, and APL cells and metabolism of ATRA may play a role in rapid clearance of ATRA after continuous oral administration.

Therapeutic strategies such as liposomal encapsulation and intermittent administration of ATRA may circumvent accelerated ATRA metabolism and improve the treatment of APL.

[MeSH-major] Colonic Neoplasms / metabolism. Cytochrome P-450 Enzyme System / metabolism. Endothelial Cells / metabolism. Gene Expression Regulation, Enzymologic. Leukemia, Promyelocytic, Acute / metabolism. Liver Neoplasms / metabolism. Tretinoin / metabolism

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Liver Cancer.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16194896.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Grant] United States / FDA HHS / FD / FDA-FD-R000923-04-01; United States / NCI NIH HHS / CA / U54 RFA CA096300

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger; 5688UTC01R / Tretinoin; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss.

We wanted to evaluate whether testing for anti-phosholipid antibodies other than anti-cardiolipin (aCL) and anti-beta-2 glycoprotein I (abeta2GPI) immunoglobulin (Ig)G and IgM identifies patients with recurrent pregnancy loss (RPL) who may be positive for anti-phospholipid syndrome (APS).

In a cross-sectional study comprising 62 patients with APS, 66 women with RPL, 50 healthy blood donors and 24 women with a history of successful pregnancies, we tested IgM and IgG antibodies to phosphatidic acid, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl inositol and phosphatidyl serine with and without beta-2 glycoprotein I (beta2GPI) from a single manufacturer as well as aCL and abeta2GPI antibodies.

Diagnostic accuracies of individual and combined anti-phospholipid (aPL) assays were assessed by computing sensitivities, specificities, positive predictive values and negative predictive values together with their 95% confidence intervals.

The overall combined sensitivity of the non-recommended aPL assays was not significantly higher than that of the aCL and aB2GPI tests.

Multiple aPL specificities in RPL group is not significantly different from controls and therefore of no clinical significance.

[MeSH-major] Abortion, Habitual / immunology. Antiphospholipid Syndrome / diagnosis

[MeSH-minor] Adolescent. Adult. Aged. Antibodies, Antiphospholipid / blood. Antibody Specificity. Autoantibodies / blood. Biomarkers / blood. Cross-Sectional Studies. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Male. Middle Aged. Pregnancy. Sensitivity and Specificity. Young Adult. beta 2-Glycoprotein I / blood

Genetic Alliance. consumer health - Pregnancy.

Genetic Alliance. consumer health - Pregnancy Loss.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Clin Pathol. 1994 May;101(5):616-24 [7909979.001]

[Cites] Blood. 1993 May 15;81(10):2618-25 [8166780.001]

[Cites] Hum Genet. 1995 Apr;95(4):385-8 [7705832.001]

[Cites] Blood. 1995 Oct 15;86(8):3083-9 [7579402.001]

[Cites] Thromb Haemost. 1995 Oct;74(4):1185-90 [8560433.001]

[Cites] Am J Clin Pathol. 1996 Oct;106(4):549-54 [8853046.001]

[Cites] Thromb Haemost. 1997 Mar;77(3):486-91 [9065999.001]

[Cites] Obstet Gynecol. 1997 Apr;89(4):549-55 [9083311.001]

[Cites] J Rheumatol. 1998 Jan;25(1):156-60 [9458221.001]

[Cites] J Clin Lab Anal. 1998;12(5):293-7 [9773961.001]

[Cites] Br J Rheumatol. 1998 Nov;37(11):1229-32 [9851275.001]

[Cites] Arthritis Rheum. 1999 Jul;42(7):1309-11 [10403256.001]

[Cites] Hum Genet. 1999 Jul-Aug;105(1-2):63-71 [10480357.001]

[Cites] Clin Chem. 2005 Mar;51(3):545-52 [15637132.001]

[Cites] Autoimmunity. 2005 Sep;38(6):425-30 [16278147.001]

[Cites] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]

[Cites] Mod Rheumatol. 2006;16(3):158-64 [16767554.001]

[Cites] Am J Clin Pathol. 2008 Jun;129(6):870-5 [18480002.001]

[Cites] Physiol Res. 2000;49(3):299-305 [11043916.001]

[Cites] Thromb Haemost. 2002 Jul;88(1):66-73 [12152681.001]

[Cites] Am J Clin Pathol. 2002 Oct;118(4):548-57 [12375642.001]

[Cites] Hum Reprod. 2002 Nov;17(11):2981-5 [12407061.001]

[Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]

[Cites] Ann Rheum Dis. 1987 Jan;46(1):1-6 [3813670.001]

[Cites] Blood. 1988 Aug;72(2):512-9 [2456797.001]

[Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120-4 [2349221.001]

[Cites] Lancet. 1990 Jun 30;335(8705):1544-7 [1972485.001]

[Cites] Blood. 1994 Nov 1;84(9):2854-67 [7949161.001]

(PMID = 18826497.001).

[ISSN] 1365-2249

[Journal-full-title] Clinical and experimental immunology

[ISO-abbreviation] Clin. Exp. Immunol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / beta 2-Glycoprotein I

[Other-IDs] NLM/ PMC2633231

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Antiphospholipid antibodies and coagulation defects in women with implantation failure after IVF and recurrent miscarriage.

Testing for antiphospholipid antibodies or thrombophilia is commonly carried out, and interpretation of results in the light of the current evidence is extremely difficult.

This paper reviews the purported pathogenetic mechanisms and clinical associations between both antiphospholipid antibodies and inherited thrombophilias, and reproductive failure.

The current management strategies are also critically evaluated and recommendations are made for optimal, evidence-based clinical practice.

[MeSH-major] Abortion, Habitual / blood. Abortion, Habitual / immunology. Antibodies, Antiphospholipid / blood. Embryo Implantation / immunology. Thrombophilia / blood

Genetic Alliance. consumer health - Recurrent spontaneous abortion.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16820106.001).

[ISSN] 1472-6483

[Journal-full-title] Reproductive biomedicine online

[ISO-abbreviation] Reprod. Biomed. Online

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Anticoagulants; 0 / Immunoglobulins, Intravenous

[Number-of-references] 96

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The antiphospholipid syndrome.

The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the clinical association of antiphospholipid autoantibodies (aPL) with a syndrome of hypercoagulability that can affect any blood vessel, irrespective of type or size.

We also discuss the impact that APS may have on pre-existing renal disease as well as current recommendations for treatment of APS.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2003 Oct 16;349(16):1526-33 [14561795.001]

[Cites] N Engl J Med. 2003 Sep 18;349(12):1133-8 [13679527.001]

[Cites] Arthritis Rheum. 2003 Nov;48(11):3272-9 [14613293.001]

[Cites] Am J Kidney Dis. 2004 Jan;43(1):28-36 [14712424.001]

[Cites] Arthritis Rheum. 2004 Apr;50(4):1226-32 [15077305.001]

[Cites] Arthritis Rheum. 2004 Aug;50(8):2569-79 [15334471.001]

[Cites] Ann Intern Med. 1992 Aug 15;117(4):303-8 [1637025.001]

[Cites] Ann Intern Med. 1992 Dec 15;117(12):997-1002 [1443986.001]

[Cites] Ann Rheum Dis. 1993 Sep;52(9):689-92 [8239766.001]

[Cites] N Engl J Med. 1995 Apr 13;332(15):993-7 [7885428.001]

[Cites] Lupus. 1996 Jun;5 Suppl 1:S16-22 [8803905.001]

[Cites] J Am Soc Nephrol. 1999 Mar;10(3):507-18 [10073601.001]

[Cites] Blood. 2004 Dec 1;104(12):3598-602 [15315975.001]

[Cites] Blood. 2005 Feb 15;105(4):1540-5 [15507529.001]

[Cites] J Thromb Haemost. 2005 May;3(5):848-53 [15869575.001]

[Cites] Ann Rheum Dis. 2005 Aug;64(8):1205-9 [15708888.001]

[Cites] J Thromb Haemost. 2006 Feb;4(2):295-306 [16420554.001]

[Cites] Blood. 2006 Mar 1;107(5):1916-24 [16269621.001]

[Cites] Rheum Dis Clin North Am. 2006 Feb;32(1):129-48, x [16504826.001]

[Cites] Arthritis Rheum. 2001 Jun;44(6):1466-7 [11407709.001]

[Cites] J Am Soc Nephrol. 2002 Jan;13(1):42-52 [11752020.001]

[Cites] N Engl J Med. 2002 Mar 7;346(10):752-63 [11882732.001]

[Cites] Arthritis Rheum. 2002 Apr;46(4):1019-27 [11953980.001]

[Cites] Rheumatology (Oxford). 2002 Aug;41(8):924-9 [12154210.001]

[Cites] Blood. 2003 Mar 1;101(5):1827-32 [12393574.001]

[Cites] Blood. 2003 May 1;101(9):3495-500 [12531807.001]

[Cites] Ann Rheum Dis. 2003 Jun;62(6):530-3 [12759289.001]

[Cites] Am J Kidney Dis. 2003 Jun;41(6):1205-11 [12776272.001]

[Cites] Lupus. 2003;12(7):530-4 [12892393.001]

[Cites] Arthritis Rheum. 2003 Nov;48(11):3004-8 [14613259.001]

(PMID = 17336687.001).

[ISSN] 0270-9295

[Journal-full-title] Seminars in nephrology

[ISO-abbreviation] Semin. Nephrol.

[Language] ENG

[Grant] None / None / / 67101; Canada / Canadian Institutes of Health Research / / 67101

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 32

[Other-IDs] NLM/ CAMS2313; NLM/ PMC3440307

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts.

METHODS: The HepASA Trial was an RCT including patients with a history of RPL and at least 1 of the following: antiphospholipid antibody (aPL), an inherited thrombophilia, or antinuclear antibody.

Treatment groups were stratified by aPL status and history of early versus late pregnancy losses.

RESULTS: Over 4 years, 859 women with RPL were screened: 88 (10.2%) fulfilled inclusion criteria, became pregnant and were randomized to receive either LMWH/ASA or ASA alone. aPL were present in 42 (47.7%) patients in each group.

Neither number of prior losses nor aPL status was correlated with pregnancy outcome.

Mean change in BMD did not differ by treatment group at either the lumbar spine (p = 0.57) or femoral neck (p = 0.15).

RCT since 2000 for aPL positive women with RPL and similar inclusion criteria report a mean live birth rate of 75% with either LMWH or ASA.

Regardless of treatment regimen, number of prior losses, or aPL positivity, almost 80% of women in our RPL cohort had a successful pregnancy outcome.

[MeSH-minor] Adult. Antibodies, Antinuclear / immunology. Anticoagulants / administration & dosage. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / drug therapy. Antiphospholipid Syndrome / physiopathology. Bone Density / drug effects. Cohort Studies. Female. Humans. Platelet Aggregation Inhibitors / administration & dosage. Pregnancy. Thrombophilia / complications. Thrombophilia / drug therapy. Thrombophilia / physiopathology. Treatment Outcome

Genetic Alliance. consumer health - Pregnancy.

Genetic Alliance. consumer health - Pregnancy Loss.

MedlinePlus Health Information. consumer health - Autoimmune Diseases.

MedlinePlus Health Information. consumer health - Bleeding Disorders.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Rheumatol. 2010 Jan;37(1):202; author reply 203 [20040643.001]

[CommentIn] Curr Rheumatol Rep. 2010 Feb;12(1):1-3 [20425526.001]

(PMID = 19208560.001).

[ISSN] 0315-162X

[Journal-full-title] The Journal of rheumatology

[ISO-abbreviation] J. Rheumatol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] Canada

[Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Anticoagulants; 0 / Heparin, Low-Molecular-Weight; 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Indications for plasma exchange in systemic lupus erythematosus in 2005.

Plasma exchange can remove putative pathogenic autoantibodies and circulating immune complexes from the blood of patients with systemic lupus erythematosus (SLE).

We review herein the principal historical steps of the use of plasma exchange to treat SLE, based upon the main trials and case reports that have highlighted its most pertinent indications.

Acute life-threatening manifestations and severe therapy-resistant manifestations, like refractory SLE renal disease, diffuse alveolar hemorrhage, neuropsychiatric SLE, thrombotic thrombocytopenic purpura, catastrophic antiphospholipid syndrome, hyperviscosity syndrome and cryoglobulinemia, are the indications for which plasma exchange might have a beneficial therapeutic role.

Although few SLE patients undergo plasma exchange each year nowadays (10-20 per year in France), adverse events are very rare and recent advances in plasma exchange technologies, like immunoadsorption, might, in the future, counterbalance their cost and broaden their place in the therapeutic armamentarium for SLE.

[MeSH-major] Lupus Erythematosus, Systemic / therapy. Plasma Exchange / methods. Plasma Exchange / trends

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Lupus.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16335578.001).

[ISSN] 0961-2033

[Journal-full-title] Lupus

[ISO-abbreviation] Lupus

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 100

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] What is the role of arsenic in newly diagnosed APL?

Acute promyelocytic leukemia (APL), a highly curable subtype of acute myeloid leukemia (AML) is characterized by the chromosomal translocation t(15;17) and, consequently, the presence of the PML-RARalpha fusion transcript.

Most patients are treated with all-trans retinoic acid (ATRA), which targets the RAR-alpha moiety of the PML/RAR-alpha fusion transcript, and anthracycline-based chemotherapy.

Arsenic trioxide (ATO) targets the PML moiety and has different mechanisms of action at different concentrations, and induces differentiation and apoptosis.

Several clinical trials have tested the combination of ATRA and ATO with outstanding results.

ATRA plus ATO has emerged as a promising strategy, even for those with high-risk disease.

[MeSH-major] Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19041605.001).

[ISSN] 1532-1924

[Journal-full-title] Best practice & research. Clinical haematology

[ISO-abbreviation] Best Pract Res Clin Haematol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Anthracyclines; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 31

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Leukemia cutis: a presenting sign in acute promyelocytic leukemia.

[MeSH-major] Leukemia, Promyelocytic, Acute / diagnosis. Skin Neoplasms / diagnosis

[MeSH-minor] Diagnosis, Differential. Female. Humans. Leg Dermatoses / diagnosis. Middle Aged

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17875899.001).

[ISSN] 0003-987X

[Journal-full-title] Archives of dermatology

[ISO-abbreviation] Arch Dermatol

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Arsenic trioxide (ATO) is an effective cancer therapeutic drug for acute promyelocytic leukemia and has potential anticancer activity against a wide range of solid tumors.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

SciCrunch. DrugBank: Data: Chemical .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Med Res Rev. 2004 Jan;24(1):40-89 [14595672.001]

[Cites] J Biol Chem. 2003 Dec 12;278(50):50226-33 [14522978.001]

[Cites] Drug Resist Updat. 2004 Apr;7(2):97-110 [15158766.001]

[Cites] Cell Death Differ. 2004 Jul;11(7):737-46 [15002036.001]

[Cites] Cell Cycle. 2004 Mar;3(3):324-34 [14726646.001]

[Cites] Biochemistry. 1982 Dec 21;21(26):6628-33 [7159551.001]

[Cites] Antioxid Redox Signal. 2007 Jan;9(1):25-47 [17115886.001]

[Cites] Carcinogenesis. 2006 Dec;27(12):2538-49 [16777982.001]

[Cites] Semin Cancer Biol. 2006 Dec;16(6):452-65 [17056271.001]

[Cites] Semin Cancer Biol. 2006 Dec;16(6):420-6 [17092741.001]

[Cites] Cancer Res. 2006 Dec 1;66(23):11416-23 [17145888.001]

[Cites] Toxicol Appl Pharmacol. 2007 Jan 1;218(1):88-95 [17156807.001]

[Cites] Leukemia. 2000 Feb;14(2):262-70 [10673743.001]

[Cites] Nature. 2000 Mar 2;404(6773):42-9 [10716435.001]

[Cites] Annu Rev Biochem. 1985;54:237-71 [3896121.001]

[Cites] J Biol Chem. 1989 Aug 25;264(24):13963-6 [2668278.001]

[Cites] J Biol Chem. 1989 Oct 5;264(28):16502-6 [2674134.001]

[Cites] Biochem Pharmacol. 1992 Apr 1;43(7):1621-7 [1567483.001]

[Cites] Methods Enzymol. 1995;252:199-208 [7476354.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6146-51 [8650234.001]

[Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3633-8 [9108029.001]

[Cites] J Biol Chem. 1998 Apr 10;273(15):8581-91 [9535831.001]

[Cites] EMBO J. 1998 May 1;17(9):2596-606 [9564042.001]

[Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]

[Cites] J Biol Chem. 1999 Feb 19;274(8):4722-34 [9988709.001]

[Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]

[Cites] J Mol Biol. 1999 Oct 8;292(5):1003-16 [10512699.001]

[Cites] Chem Res Toxicol. 1999 Oct;12(10):924-30 [10525267.001]

[Cites] Anticancer Drugs. 2005 Feb;16(2):119-27 [15655408.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8 [15637150.001]

[Cites] Blood. 2005 Feb 1;105(3):1237-45 [15466933.001]

[Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):348-66 [15706083.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2396-410 [15800332.001]

[Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]

[Cites] Nat Methods. 2004 Oct;1(1):61-6 [15782154.001]

[Cites] Free Radic Biol Med. 2005 Jun 15;38(12):1543-52 [15917183.001]

[Cites] Oncogene. 2005 Jun 2;24(24):3853-63 [15824742.001]

[Cites] J Biol Chem. 2005 Jul 1;280(26):25284-90 [15879598.001]

[Cites] Hematology. 2005 Jun;10(3):205-13 [16019469.001]

[Cites] Free Radic Biol Med. 2005 Sep 1;39(5):696-703 [16085187.001]

[Cites] Front Biosci. 2006;11:300-12 [16146732.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15018-23 [16217027.001]

[Cites] Trends Mol Med. 2005 Dec;11(12):571-8 [16290020.001]

[Cites] Free Radic Biol Med. 2006 Jan 1;40(1):138-45 [16337887.001]

[Cites] J Biol Chem. 2006 Apr 21;281(16):10691-7 [16481328.001]

[Cites] Cancer Res. 2006 Apr 15;66(8):4410-8 [16618767.001]

[Cites] J Biol Chem. 2006 May 12;281(19):13005-8 [16565519.001]

[Cites] Mutat Res. 2006 Jun;612(3):215-46 [16574468.001]

[Cites] Biochem Biophys Res Commun. 2006 Jul 21;346(1):242-51 [16756956.001]

[Cites] Cancer Cell. 2006 Sep;10(3):175-6 [16959608.001]

[Cites] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1881-90 [16987040.001]

[Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5854-9 [10801974.001]

[Cites] J Biol Chem. 2000 Jun 16;275(24):18121-8 [10849437.001]

[Cites] Eur J Biochem. 2000 Oct;267(20):6102-9 [11012661.001]

[Cites] Free Radic Biol Med. 2000 Aug;29(3-4):312-22 [11035260.001]

[Cites] J Pharmacol Exp Ther. 2001 Jan;296(1):1-6 [11123355.001]

[Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]

[Cites] Cell Mol Life Sci. 2000 Dec;57(13-14):1825-35 [11215509.001]

[Cites] J Physiol. 2001 Feb 15;531(Pt 1):1-11 [11179387.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3673-8 [11259642.001]

[Cites] Chem Res Toxicol. 2001 May;14(5):517-22 [11368549.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9533-8 [11481439.001]

[Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):127-44 [11601889.001]

[Cites] Free Radic Biol Med. 2001 Nov 15;31(10):1170-8 [11705695.001]

[Cites] Breast Cancer Res Treat. 2002 May;73(1):61-73 [12083632.001]

[Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]

[Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]

[Cites] Cell Mol Life Sci. 2002 Nov;59(11):1972-82 [12530527.001]

[Cites] Science. 2003 May 30;300(5624):1439-43 [12775843.001]

(PMID = 17640917.001).

[ISSN] 0027-8424

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Enzyme Inhibitors; 0 / Oxides; EC 1.8.1.9 / Thioredoxin-Disulfide Reductase; GAN16C9B8O / Glutathione; S7V92P67HO / arsenic trioxide

[Other-IDs] NLM/ PMC1940330

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Determination of non-bilayer phospholipid arrangements and their antibodies in placentae and sera of patients with hypertensive disorders of pregnancy.

Antiphospholipid antibodies (APA) in circulation are also associated with vascular diseases.

In fact, the pathology of placentae from PE and Antiphospholipid syndrome patients is similar; atherosis, thrombosis and infarction, and endothelium activation represent the pathological mechanisms.

We identified a new antibody which recognizes non-bilayer phospholipid arrangements (NPA) in membrane models and in cell membranes in vivo, and which triggered an autoimmune-like disease in mice.

Results showed increased levels of NPA in the syncytiotrophoblast, extravillous cytotrophoblast, syncytial knots and the amnion epithelial cell membranes of the placenta, as well as increases in NPA and NPA antibodies in sera from HDP patients, when compared with controls.

[MeSH-major] Antibodies, Antiphospholipid / analysis. Membrane Lipids / analysis. Phospholipids / analysis. Placenta / chemistry. Pre-Eclampsia / etiology

Genetic Alliance. consumer health - Pregnancy.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16338467.001).

[ISSN] 0143-4004

[Journal-full-title] Placenta

[ISO-abbreviation] Placenta

[Language] eng

[Grant] United States / NICHD NIH HHS / HD / HD40363

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Membrane Lipids; 0 / Phospholipids

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advances in management of acute promyelocytic leukemia with arsenic trioxide.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17609904.001).

[ISSN] 1672-0415

[Journal-full-title] Chinese journal of integrative medicine

[ISO-abbreviation] Chin J Integr Med

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Water-soluble CdTe quantum dots synthesized in aqueous solution have been conjugated with peptide LyP-1 using N-Succinimidyl 3-[2-pyridyldithio]-propionate (SPDP) as a cross-linking reagent.

Capillary electrophoresis (CE), UV-Vis absorption and photoluminescent (PL) spectra suggested that the peptide had been successfully linked to the QDs.

The QDs-peptides conjugates could specifically recognize the lung adenoma cancer cells (SPCA-1), but did not recognize promyelocytic leukemia cells (HL-60).

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17713265.001).

[ISSN] 1001-5515

[Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi

[ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / LyP-1 protein, mouse; 0 / Oligopeptides; 0 / Peptides; 0 / Peptides, Cyclic; 99896-85-2 / arginyl-glycyl-aspartic acid

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction.

Interferon (IFN) induces expression of proapoptotic genes and has been used in the clinical treatment of multiple myeloma.

The promyelocytic leukemia (PML) gene is an IFN-induced target that encodes a tumor suppressor protein.

PML protein is typically localized within discrete speckled nuclear structures termed PML nuclear bodies (NBs).

Herein, we show that growth inhibition effects of IFN-alpha in myeloma cells correlate with PML NBs and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induction, whereas known IFN targets including signal transducer and activator of transcription-1 (STAT1), STAT3, p38, and Daxx cannot account for these differential responses.

RNAi silencing of PML blocks IFN-alpha-induced apoptosis in myeloma cells and correspondingly down-regulates TRAIL expression.

These results demonstrate that PML and TRAIL play important roles in IFN-induced apoptosis and identify TRAIL as a novel downstream transcriptional target of PML.

Identification of PML and PML NBs as effectors of IFN responses provides insights into mechanisms by which tumor cells exhibit resistance to this class of agents and may prove useful in assessing treatment regimens.

[MeSH-major] Apoptosis / drug effects. Interferon-alpha / pharmacology. Membrane Glycoproteins / physiology. Neoplasm Proteins / physiology. Nuclear Proteins / physiology. Transcription Factors / physiology. Tumor Necrosis Factor-alpha / physiology

[MeSH-minor] Apoptosis Regulatory Proteins. Cell Division / drug effects. Cell Line, Tumor. Humans. Leukemia, Promyelocytic, Acute. Multiple Myeloma. RNA, Small Interfering / genetics. TNF-Related Apoptosis-Inducing Ligand. Transfection. Tumor Suppressor Proteins

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15459016.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Interferon-alpha; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

When cell-permeating fluorescent dyes were used as indicators of the generation of reactive oxygen species (ROS), we found that PAT treatment directly increased intracellular oxidative stress in human embryonic kidney (HEK293) and human promyelocytic leukemia (HL-60) cells.

Lipid peroxidation levels were also significantly increased in HL-60 cells and mouse kidney homogenates treated with PAT.

Pretreatment of HEK293 cells with Tiron, a free radical scavenger, reduced the phosphorylation levels of extracellular signal-regulated kinase (ERK) 1/2 elicited by PAT.

The ERK1/2 signaling pathway inhibitor, U0126, also significantly decreased the levels of ROS associated with PAT treatment.

Hazardous Substances Data Bank. PATULIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17090621.001).

[ISSN] 1096-6080

[Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology

[ISO-abbreviation] Toxicol. Sci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Free Radical Scavengers; 0 / Reactive Oxygen Species; 95X2BV4W8R / Patulin; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adenovirus type 5 E4orf3 protein targets the Mre11 complex to cytoplasmic aggresomes.

Rearrangement of Mre11 and Rad50 by Ad5 E4orf3 is not dependent on interactions with Nbs1 or promyelocytic leukemia protein nuclear bodies.

COS Scholar Universe. author profiles.

Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Virol. 1989 Jun;63(6):2605-15 [2724411.001]

[Cites] J Virol. 2005 Jun;79(11):6664-73 [15890904.001]

[Cites] EMBO J. 1990 Aug;9(8):2621-9 [2142453.001]

[Cites] J Struct Biol. 1990 May;103(3):280-9 [2261312.001]

[Cites] J Virol. 1991 Jan;65(1):424-9 [1824641.001]

[Cites] J Virol. 1992 May;66(5):3140-50 [1560540.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):153-7 [8278357.001]

[Cites] Virology. 1999 Oct 25;263(2):307-12 [10544104.001]

[Cites] Science. 1999 Dec 3;286(5446):1888-93 [10583944.001]

[Cites] J Cell Physiol. 1994 Jul;160(1):47-60 [8021299.001]

[Cites] EMBO J. 1994 Nov 1;13(21):5075-85 [7957073.001]

[Cites] J Cell Biol. 1995 Oct;131(1):45-56 [7559785.001]

[Cites] Genes Dev. 1996 Jan 15;10(2):196-207 [8566753.001]

[Cites] J Virol. 1996 Sep;70(9):6323-35 [8709260.001]

[Cites] EMBO J. 1997 Jul 16;16(14):4276-84 [9250671.001]

[Cites] J Gen Virol. 1997 Sep;78 ( Pt 9):2131-8 [9291998.001]

[Cites] Curr Opin Cell Biol. 1998 Feb;10(1):52-9 [9484595.001]

[Cites] Cell. 1998 May 1;93(3):477-86 [9590181.001]

[Cites] J Cell Biol. 1998 Dec 28;143(7):1883-98 [9864362.001]

[Cites] J Virol. 1999 Mar;73(3):2253-62 [9971808.001]

[Cites] J Gen Virol. 1999 Apr;80 ( Pt 4):997-1008 [10211970.001]

[Cites] Cell. 1999 Dec 10;99(6):577-87 [10612394.001]

[Cites] Trends Cell Biol. 1999 Dec;9(12):M42-5 [10611680.001]

[Cites] J Virol. 2000 Dec;74(23):11407-12 [11070042.001]

[Cites] Trends Cell Biol. 2000 Dec;10(12):524-30 [11121744.001]

[Cites] Mol Cell Biol. 2001 Mar;21(6):2184-91 [11238951.001]

[Cites] Nat Genet. 2001 Apr;27(4):417-21 [11279524.001]

[Cites] J Cell Biol. 2001 Apr 30;153(3):449-55 [11331297.001]

[Cites] Gene. 2001 Oct 31;278(1-2):1-23 [11707318.001]

[Cites] J Virol. 2002 Feb;76(3):1475-87 [11773420.001]

[Cites] J Virol. 2002 May;76(9):4507-19 [11932416.001]

[Cites] Traffic. 2002 Jun;3(6):388-96 [12010457.001]

[Cites] Nature. 2002 Jul 18;418(6895):348-52 [12124628.001]

[Cites] J Gen Virol. 2003 Feb;84(Pt 2):259-68 [12560556.001]

[Cites] J Virol. 2003 May;77(9):5295-304 [12692231.001]

[Cites] EMBO J. 2003 Dec 15;22(24):6610-20 [14657032.001]

[Cites] J Virol. 2004 Jan;78(1):441-53 [14671124.001]

[Cites] Cell. 2003 Dec 12;115(6):727-38 [14675537.001]

[Cites] Nat Med. 2004 Jul;10 Suppl:S10-7 [15272267.001]

[Cites] J Virol. 2004 Sep;78(18):9924-35 [15331726.001]

[Cites] Exp Cell Res. 2004 Oct 1;299(2):486-97 [15350546.001]

[Cites] J Mol Biol. 1982 Dec 15;162(3):565-83 [7166756.001]

[Cites] Eur J Cell Biol. 1984 Jul;34(2):313-22 [6236979.001]

[Cites] J Virol. 1985 Oct;56(1):250-7 [4032537.001]

[Cites] Virology. 1985 Apr 15;142(1):44-58 [2932843.001]

[Cites] J Virol. 1986 Mar;57(3):833-8 [3485200.001]

[Cites] Oncogene. 1988 Jun;2(6):579-84 [3290806.001]

[Cites] J Cell Biol. 1999 Sep 20;146(6):1239-54 [10491388.001]

[Cites] Oncogene. 2005 Jan 6;24(1):55-64 [15480414.001]

[Cites] J Virol. 2005 May;79(10):6207-15 [15858005.001]

[Cites] Virology. 1990 Feb;174(2):345-53 [2137659.001]

(PMID = 16103189.001).

[ISSN] 0022-538X

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA097093; United States / NIAID NIH HHS / AI / AI43341; United States / NCI NIH HHS / CA / CA97093

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Adenovirus E4 Proteins; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / MRE11A protein, human; 0 / Multiprotein Complexes; 0 / NBN protein, human; 0 / Nuclear Proteins; 0 / Rad50 protein, human; 0 / Tubulin; EC 6.5.1.- / DNA Repair Enzymes

[Other-IDs] NLM/ PMC1193610

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Antiphospholipid syndrome. Current insights into laboratory diagnosis and pathophysiology.

The antiphospholipid syndrome (APS) is a non-inflammatory autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL) in the plasma of patients with vascular thrombosis, recurrent complications of pregnancy, or both (1, 2).

The presence of aPL in plasma of patients can be detected with either a prolongation of phospholipid dependent coagulation tests (lupus anticoagulant, LAC), or with solid phase immune assays against the protein beta2-glycoprotein I (beta2-GPI) or the phospholipid cardiolipin (anti-beta2-GPI antibody ELISA and anti-cardiolipin antibody ELISA, respectively) (3).

To solve this dispute, an international consensus meeting was organized in Sapporo in 1999 to formulate classification criteria for patients with the antiphospholipid syndrome (4).

This is very unfortunate because the specificity of the different aPL assays to detect the clinical manifestations that characterize APS are disputable.

One of the aims of defining the criteria was to initiate studies to determine the value of the different anti-phospholipid antibody assays to serve as biomarker for the risk of thrombosis and pregnancy morbidity.

[MeSH-major] Antiphospholipid Syndrome / diagnosis. Antiphospholipid Syndrome / physiopathology

[MeSH-minor] Antibodies, Antiphospholipid / blood. Antibodies, Antiphospholipid / physiology. Clinical Laboratory Techniques. Female. Humans. Pregnancy. Pregnancy Complications / blood

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20680233.001).

[ISSN] 0720-9355

[Journal-full-title] Hämostaseologie

[ISO-abbreviation] Hamostaseologie

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Blood lactate concentration [LAC] is considered a useful indicator of disease severity in horses.

HYPOTHESIS: It was hypothesized that results from a POC lactate monitor would be in agreement with a laboratory-based measurement of [LAC].

[LAC] was measured with whole blood (AWB) and plasma (APL) by means of a POC monitor (Accutrend) and compared with results from whole blood measured by a laboratory blood gas analyzer (NOVA).

Agreement (p +/- SE) was closest between APL and NOVA (0.97 +/- 0.01); an average observed difference of 0.15 +/- 0.89 (mean +/- SD) and 95% limits of agreement (LOA) -1.89, 1.59 also were found.

CONCLUSIONS AND CLINICAL IMPORTANCE: Results indicate close agreement between NOVA and the POC monitor when [LAC] was measured with plasma.

MedlinePlus Health Information. consumer health - Emergency Medical Services.

Hazardous Substances Data Bank. LACTIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17939569.001).

[ISSN] 0891-6640

[Journal-full-title] Journal of veterinary internal medicine

[ISO-abbreviation] J. Vet. Intern. Med.

[Language] ENG

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 33X04XA5AT / Lactic Acid

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome.

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial and venous thrombosis, recurrent abortions, and antiphospholipid antibodies (aPL).

However, it is possible to find patients with clinical signs of APS who persistently test negative for aPL (seronegative APS, or SN-APS).

We tested sera from patients with SN-APS with a proteomic approach by analyzing endothelial cell-surface membrane proteins.

Our results prompt to identify vimentin as a "new" cofactor for aPL, which may represent a useful tool mainly in SN-APS patients.

[MeSH-major] Antiphospholipid Syndrome / diagnosis. Autoantibodies / immunology. Cardiolipins / immunology. Vimentin / immunology

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2010 Oct 21;116(16):2867-9 [20966174.001]

(PMID = 20634382.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Autoantibodies; 0 / Cardiolipins; 0 / NF-kappa B; 0 / Vimentin; EC 2.7.11.1 / IRAK1 protein, human; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Venous thrombosis and pulmonary embolism in a child with pneumonia due to Mycoplasma pneumoniae.

A 13-year-old boy with Mycoplasma pneumoniae pulmonary infection developed deep vein thrombosis and pulmonary embolism.

He was found to have protein S deficiency and transient antiphospholipid antibodies.

Though uncommon, it is important to consider venous thromboembolic disease in children whose clinical course is atypically severe.

[MeSH-major] Lupus Erythematosus, Systemic / complications. Pneumonia, Mycoplasma / complications. Pulmonary Embolism / etiology. Venous Thrombosis / etiology

[MeSH-minor] Adolescent. Anticoagulants / therapeutic use. Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / immunology. Heparin / therapeutic use. Humans. Male. Protein S Deficiency / complications. Protein S Deficiency / immunology. Warfarin / therapeutic use

Genetic Alliance. consumer health - Embolism.

Genetic Alliance. consumer health - Thrombosis.

MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

MedlinePlus Health Information. consumer health - Lupus.

MedlinePlus Health Information. consumer health - Pulmonary Embolism.

Hazardous Substances Data Bank. WARFARIN .

Hazardous Substances Data Bank. HEPARIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19806855.001).

[ISSN] 1943-4693

[Journal-full-title] Journal of the National Medical Association

[ISO-abbreviation] J Natl Med Assoc

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin; 9005-49-6 / Heparin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome.

The symptoms appeared one day after start of the treatment with fluvastatin (40 mg) administered in order to diminish the endothelial activation induced by antiphospholipid antibodies (aPL).

The patient suffered from severe manifestations of the antiphospholipid syndrome (APS) including Catastrophic Antiphospholipid Syndrome (CAPS, Asherson's syndrome).

[MeSH-major] Antiphospholipid Syndrome / complications. Epilepsies, Partial / chemically induced. Fatty Acids, Monounsaturated / adverse effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects. Indoles / adverse effects. Seizures / chemically induced

Genetic Alliance. consumer health - Catastrophic Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Seizures.

MedlinePlus Health Information. consumer health - Seizures.

MedlinePlus Health Information. consumer health - Statins.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16111706.001).

[ISSN] 0022-510X

[Journal-full-title] Journal of the neurological sciences

[ISO-abbreviation] J. Neurol. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Fatty Acids, Monounsaturated; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Indoles; 4L066368AS / fluvastatin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies.

AIM: To determine the prevalence of antiphospholipid syndrome nephropathy (APSN) in Thai systemic lupus erythematosus (SLE) patients who underwent renal biopsy and to compare the relationship of renal histopathology and other significant clinical parameters between SLE patients with and without APSN.

METHODS: A retrospective analysis was undertaken in systemic lupus erythematosus patients (n = 150, 44 <15 years old, 106 0e;15 years old) who underwent renal biopsy.

The specimens were evaluated for histological features of APSN and other significant clinical parameters.

The result of antiphospholipid antibodies, clinical course, and renal function from chart review were analysed.

RESULTS: The prevalence of APSN in systemic lupus erythematosus patients who underwent renal biopsies was 34% (16% in <15-year-old group, 41.5% in > or =15-year-old group).

APSN was associated with more severe hypertension (P = 0.002 for systolic and P = 0.004 for diastolic blood pressure), acute renal failure (P = 0.003), persistent heavy proteinuria (P < 0.001 for 4+ proteinuria), severe lupus nephritis (class III and IV, P = 0.014, high activity and chronicity indices, P < 0.001) and a tendency to progress to end-stage renal disease.

[MeSH-major] Antiphospholipid Syndrome / complications. Antiphospholipid Syndrome / epidemiology. Kidney / pathology. Kidney Diseases / etiology. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / physiopathology

[MeSH-minor] Adolescent. Adult. Biopsy. Child. Child, Preschool. Chronic Disease. Disease Progression. Female. Humans. Infant. Kidney Failure, Chronic / etiology. Male. Middle Aged. Prevalence. Retrospective Studies. Severity of Illness Index. Thailand

Genetic Alliance. consumer health - Lupus.

Genetic Alliance. consumer health - Antiphospholipid Syndrome.

Genetic Alliance. consumer health - Systemic lupus erythematosus.

MedlinePlus Health Information. consumer health - Kidney Diseases.

MedlinePlus Health Information. consumer health - Lupus.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17803471.001).

[ISSN] 1320-5358

[Journal-full-title] Nephrology (Carlton, Vic.)

[ISO-abbreviation] Nephrology (Carlton)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Australia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lung adenocarcinoma and antiphospholipid antibodies.

Thrombosis is a frequent finding in cancer patients, being referred to as a poor prognostic factor.

A number of studies have demonstrated the presence of antiphospholipid antibodies (aPL) in cancer patients, suggesting a potential role in tumor-associated thrombosis.

A prospective analysis has been performed in a group of lung adenocarcinoma patients in respect to the presence of aPL and thrombotic manifestations.

On the other hand, patients that displayed IgM anti-beta2-glycoprotein I (abeta2GPI) (22/80) showed an unexpected decrease in thrombosis risk (2/22, with IgM abeta2GPI vs 18/58, without IgM abeta2GPI RR=0.29; p=0.04).

Considerations on the mechanisms that link cancer, thrombosis and aPL are discussed in this article.

[MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Antibodies, Antiphospholipid / blood. Lung Neoplasms / diagnosis. Lung Neoplasms / immunology

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19185619.001).

[ISSN] 1873-0183

[Journal-full-title] Autoimmunity reviews

[ISO-abbreviation] Autoimmun Rev

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantibodies; 0 / Immunoglobulin M; 0 / Lupus Coagulation Inhibitor; 0 / beta 2-Glycoprotein I

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan.

It is a specific agonist for retinoic acid receptor alpha/beta.

Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells.

In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein.

Furthermore, adverse side effects were milder than those of ATRA in clinical trials.

Clinical trials held in Japan showed that tamibarotene had efficacy in APL patients who had relapsed from ATRA-induced complete remission.

Tamibarotene is being investigated for treatment of multiple myeloma and Crohn's disease in clinical trials.

This review focuses on tamibarotene's mechanisms of action, chemical properties, pharmacokinetics and its use in APL as well as its potential use in various disorders.

[MeSH-major] Antineoplastic Agents / therapeutic use. Benzoates / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tetrahydronaphthalenes / therapeutic use

[MeSH-minor] Animals. Controlled Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

SciCrunch. DrugBank: Data: Chemical .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Prous Science.

(PMID = 17925887.001).

[ISSN] 1699-3993

[Journal-full-title] Drugs of today (Barcelona, Spain : 1998)

[ISO-abbreviation] Drugs Today

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Spain

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Tetrahydronaphthalenes; 08V52GZ3H9 / tamibarotene

[Number-of-references] 38